MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Hyposmia as a biomarker in patients with Parkinson’s disease and atypical Parkinsonism

S. Kumaran, A. Ankeeta, S. Chaudhary, P. Bhat, V. Goyal (New Delhi, India)

Meeting: MDS Virtual Congress 2020

Abstract Number: 591

Keywords: Cognitive dysfunction, Olfactory dysfunction, Parkinsonism

Category: Parkinson's Disease: Neuroimaging

Objective: To investigate neural correlates associated with olfactory dysfunction using fMRI and EEG in Parkinsonism.

Background: Patients with Parkinsonism experience non-motor symptoms during the onset and progress of disease. Hyposmia may be a characteristic sign of Parkinson’s disease (PD), as revealed by electrophysiological studies, with over 95% patients with significant olfactory loss [1-2].

Method: All right handed PD (25), MSA (16) and PSP (16) patients (Table 1) were recruited from the movement disorder clinics of our institute. Standard diagnostic and exclusion criteria were followed. MR studies were carried out in a 3T MR scanner using 32 channel head coils (M/s. Philips, the Netherlands) in the “on” state. Echo planar imaging sequence was used for functional MRI studies using a block design. The patients underwent sniff kit (Burghart Messtechnik GmbH, Germany) test during the active state and a period of rest (no smell) during the baseline state. Data was analysed using SPM12 and EEG lab [3-4]. Two sample t-test (p<0.05, cluster threshold 10) was used for group analysis. Spearman correlation analysis was done by using STATA (ver. 12) for testing  level of significance. Multiple comparisons was done using Bonferroni post-hoc test, Kruskal-wallis test.

Results: All patient groups had less activation in olfaction areas (Parkinson’s disease < MSA < PSP). Activation was absent in middle frontal, orbitofrontal, and temporal cortex, inferior frontal, insular, and cingulate cortex in patients with Parkinson’s disease (Figure 1). In patients with MSA and PSP, activation was observed in bilateral middle frontal, orbito-frontal cortex; left hemispheric inferior frontal, temporal, and cingulate cortex areas [3]. EEG revealed a similar pattern on frequency change of Delta waveform in PD and MSA groups, but PSP exhibited different pattern in the alpha waveform. Alteration in the spectral powers (increases in delta and theta; decrease in alpha and beta; less significant in gamma) in PD and MSA patients for smell detection and identification revealed a similar trend, and was different in PSP group.

Conclusion: Differential brain activation pattern was observed in PD, MSA and PSP during hyposmia task. EEG exhibited different frequency of spectral power delta and alpha waves and a positive correlation with the clinical score in the frontal cortex suggesting its role in the signal transmission to temporal and cingulate regions.

mds

mds figure1

References: 1. Iannilli E Stephan L, Hummel T, Reichmann H, Haehner A. 2017. Olfactory impairment in Parkinson’s disease is a consequence of central nervous system decline. J Neurol. 264:1236-1246 2. 2. Haehner A, Hummel T, Reichmann H. 2009. Olfactory dysfunction as a diagnostic marker for Parkinson’s disease. Expert Rev Neurother. 912:1773-9 3. 3. Friston KJ 2003. Learning and inference in the brain. Neural Netw.16:1325–52 4. 4. Delorme A, Makeig S 2004. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics. Journal of Neuroscience Methods. 134:9-21.

To cite this abstract in AMA style:

S. Kumaran, A. Ankeeta, S. Chaudhary, P. Bhat, V. Goyal. Hyposmia as a biomarker in patients with Parkinson’s disease and atypical Parkinsonism [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/hyposmia-as-a-biomarker-in-patients-with-parkinsons-disease-and-atypical-parkinsonism/. Accessed June 4, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/hyposmia-as-a-biomarker-in-patients-with-parkinsons-disease-and-atypical-parkinsonism/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley